Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Logo
MNKD US​

Mannkind Corp(MNKD US)

$3.19-0.010.31%Ext:$3.43+0.247.44%(Market Closed · 23:47:19 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Mannkind Corp — Company Profile

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
Michael E. Castagna
Headquarters
Danbury, CT, US
IPO Date
Jul 28, 2004
Employees
592
Website
www.mannkindcorp.com

Key Metrics

Price
$3.80
Market Cap
$1.21B
Revenue (TTM)
$90.17M
Net Income (TTM)
$-16619000.00
EPS (TTM)
-0.05
P/E (TTM)
-50.75
P/B (TTM)
-20.50
Dividend Yield
0.00%
ROE (TTM)
28.08%
ROA (TTM)
-2.23%
Operating Margin
-3.31%
Beta
0.80

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.

Website
www.mannkindcorp.com
Location
Danbury, CT, US
Phone818 661 5000
Employees592
CEOMichael E. Castagna
Sector
Health Care
Industry
Pharmaceuticals
IPO DateJul 28, 2004

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(1.7K)

Expand
  • 4Statement of changes in beneficial ownership28 Sep
  • 144Binder Steven B.25 Sep
  • 4Statement of changes in beneficial ownership14 Sep
  • 144Binder Steven B.10 Sep
  • 8-KOther Events21 Aug
  • 424B7Prospectus filing (Rule 424(b)(7))21 Aug
  • SC 13GMANNKIND CORP14 Aug
  • 4Statement of changes in beneficial ownership10 Aug
  • 144Binder Steven B.7 Aug
  • 10-QQ2ended 30 Jun 20265 Aug
  • 8-KResults of Operations and Financial Condition5 Aug
  • SC 13GMANNKIND CORP31 Jul
  • 8-KMannKind Announces $50 Million Private Placement24 Jul
  • 4Statement of changes in beneficial ownership17 Jul
  • 4Statement of changes in beneficial ownership17 Jul
  • 4Statement of changes in beneficial ownership17 Jul
  • 4Statement of changes in beneficial ownership17 Jul
  • 4Statement of changes in beneficial ownership17 Jul
  • 4Statement of changes in beneficial ownership17 Jul
  • 4Statement of changes in beneficial ownership17 Jul

News

  • MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth20 Oct
  • This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday19 Oct
  • MannKind to Participate in the Chardan Healthcare Conference14 Oct
  • MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)9 Oct
  • MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum17 Sep
  • Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule9 Sep
  • MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management9 Sep
  • MannKind to Present at Upcoming Investor Conferences2 Sep
  • FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH28 Aug
  • MannKind: New Approvals Majorly Increase MannKind's Prospects13 Aug
  • MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript5 Aug
  • MannKind Q2 Earnings Call Highlights5 Aug
  • Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics5 Aug
  • MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates5 Aug
  • MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update5 Aug
  • MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript30 Jul
  • MannKind's Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway29 Jul
  • MannKind injection helps heart failure patients avoid ER infusions29 Jul
  • MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF29 Jul
  • MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 202628 Jul

Mentions in Filings

  • … between Teofilo Raad and the Company Form 8-K (Exhibit 10.2) 01/08/24 001-36199 10.19 Bill of Sale and Assignment Agreement, dated as of May 28, 2024, by and between Pulmatrix, Inc. and <strong>MannKind Corporation</strong> Form 10-Q (Exhibit 10.4) 08/13/24 001-36199 10.20 Intellectual Property Cross License Agreement, dated as of May 28, 2024, by and between Pulmatrix, Inc. and MannKind Corporatio …
    Pulmatrix, Inc.Mannkind Corp·ARS - Annual report to security holders·FY25·5 Oct
  • … cancer and chronic infectious disease; he also founded AlleCure Corp., of Valencia, California, a developer of allergy treatments and immune modulating therapies. In 2001, AlleCure and CTL ImmunoTherapies merged to form <strong>MannKind</strong> Corp., where Mr. Simard served as Corporate Vice President and a board member. Mr. Simard holds a degree in Biochemistry from the University of Saskatchewan and attended graduate studies in Medical Biophysics/Immunology …
    XBiotech Inc.Mannkind Corp·DEF 14A - Definitive proxy statement·Q4 26·2 Oct
  • … rganizations. Pulmatrix has historically supported an internal research and development team and facility for their pipeline and other potential development programs, however following the closing of the transaction with <strong>MannKind</strong> Corporation (“MannKind” and such transactions, the “MannKind Transaction”) in the year ended December 31, 2024, the majority of their research and development employees were terminated and their facility lease was assign …
    Pulmatrix, Inc.Mannkind Corp·424B3 - Prospectus filing (Rule 424(b)(3))·Q3 26·25 Sep
  • … al excellence, and global markets, supporting the Board’s oversight in these critical areas. Ms. Mundkur’s public company board experience further enhances her contributions, including her current service on the board of <strong>MannKind</strong>, where she serves on the Audit and the Nominating and Corporate Governance Committees. Her combined operational, regulatory, and governance experience provides the Board with a well rounded perspective on complex regulat …
    CARDINAL HEALTH INCMannkind Corp·DEF 14A - DEFINITIVE PROXY STATEMENT·Q2 27·21 Sep
  • … | $ | 7,806 | | $ | (7,806 | ) | | Operating expenses: | | | | | | | | | | | Research and development | | 38 | | | 7,166 | | | (7,128 | ) | | General and administrative | | 5,131 | | | 7,785 | | | (2,654 | ) | | Loss on <strong>MannKind</strong> Transaction | | - | | | 2,618 | | | (2,618 | ) | | Total operating expenses | | 5,169 | | | 17,569 | | | (12,400 | ) | | Loss from operations | | (5,169 | ) | | (9,763 | ) | | 4,594 | | | Other income (expense): | | | | …
    Pulmatrix, Inc.Mannkind Corp·DEFM14A - Definitive proxy statement (merger)·Q3 26·25 Sep
  • … trix, Inc.’s Current Report on Form 8-K (File No. 001-36199) filed with the SEC on February 16, 2021). | | 10.23 | Bill of Sale and Assignment Agreement, dated as of May 28, 2024, by and between Pulmatrix, Inc. and <strong>MannKind Corporation</strong> (incorporated by reference to Exhibit 10.4 to Pulmatrix, Inc.’s Quarterly Report on Form 10-Q (File No. 001-36199) filed with the SEC on August 13, 2024). | | 10.24 | Intellectual Property Cross License Agreement, …
    Pulmatrix, Inc.Mannkind Corp·S-4/A - Registration statement (business combination, amendment)·Q3 26·23 Sep

Key Stats

Trading

Px/Chg 1D$3.80 / -3.80%
Avg Volume6.36M
Beta0.80
Mkt Cap1.21B
FD Mkt Cap1.25B

Float

Shrs Out/Float319.39M / 303.10M
Short Float0.09%
Days to Cover4.41
Stock Repurchased$0.00

Current Valuation

EV1.60B
EV/EBITDA57.98
EV/Sales4.43
P/B-20.50
P/S3.36
FCF Yield-0.62%
ROE28.08%
ROA-2.23%
Current Ratio1.87

Estimates

P/E-50.75
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-38.20-11.41-99.9848.24-54.81-73.03
Price / Sales8.3910.006.004.667.8113.46
Price / Book Value-12.67-3.98-4.85-16.89-17.13-20.50
Price / Free Cash Flow-72.58-11.30-142.9940.55-87.83-161.31
ENTERPRISE VALUE METRICS
Enterprise Value1,329.31,216.11,227.71,332.31,272.61,597.5
Enterprise Value / Sales10.4212.196.174.6711.3717.72
Enterprise Value / EBITDA44.52-21.5981.1517.20-506.22652.05
Enterprise Value / EBIT-90.78-19.42115.8919.45-163.53-406.29

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue46.7%75.499.8199.0285.5349.0
Gross Income67.5%36.642.3136.2208.9287.8
EBITDA—-61.1-56.315.177.527.5
EBIT—-64.3-62.610.668.515.2
Net Income—-80.9-87.4-11.927.65.9
EPS (Diluted)—-0.37-0.44-0.040.100.02
BALANCE SHEET
Cash & ST Inv-4.3%204.1170.8295.1197.3171.3
Total Assets25.3%321.2295.3475.2393.8792.2
Total Liabilities12.3%530.5545.8721.4472.7843.2
Total Shareholder Equity-29.7%-209.3-250.5-246.2-78.8-51.0
CASH FLOW
Net Operating Cash Flow—-61.7-80.734.142.518.3
Cap Ex-20.6%-11.5-7.6-42.4-9.7-4.6
Free Cash Flow—-73.2-88.3-8.332.813.7

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)3.20
Basic Shares319.39
Market Cap1,020.5
Diluted Shares308.27
Fully Diluted Shares Outstanding308.27
Fully Diluted Market Cap984.9
+Consolidated Debt436.7
−In-the-Money Convertible Debt—
+Capital Leases103.1
+Operating Leases—
−Cash & Equivalents-52.8
−Short-term Investments-81.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value1,404.3

Segment data

Revenue

by Products and services

  • Product Revenue62%
  • Royalty37%
  • Service1%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US